Navigation Links
Critical element that improves vascular function in postmenopausal women found
Date:2/14/2012

at suggests estrogen may benefit arteries by maintaining BH4 levels," Moreau said. "Having adequate BH4 levels would result in increased nitric oxide and decreased free radicals, promoting vasodilatation and reducing arterial stiffness."

It has been long known that menopause has significant impacts on women's health.

"Menopause is like an accelerated aging process," Moreau said."When women hit menopause you see this dramatic decline in arterial health." Moreau's discovery of the key role BH4 plays in this process sheds more light on the decline in arterial health and why it may not be inevitable.

"As we identify the causes of the vascular health decline we can next intervene with appropriate therapeutic strategies including exercise, diet and/or hormone therapy," she said. "Heart disease is the number one killer of men and women but it is underappreciated in women who need a better understanding of cardiovascular health."


'/>"/>
Contact: David Kelly
david.kelly@ucdenver.edu
303-315-6374
University of Colorado Denver
Source:Eurekalert

Page: 1 2

Related biology news :

1. Satellite study reveals critical habitat and corridors for worlds rarest gorilla
2. Stealthy leprosy pathogen evades critical vitamin D-dependent immune response
3. Berkeley Lab researchers discover critical rotational motion in cells
4. Fungi-filled forests are critical for endangered orchids
5. Researchers find gene critical to sense of smell in fruit fly
6. Scripps Research Scientist wins pair of grants to study critical component of memory
7. Mutation in gene thats critical for human development linked to arrhythmia
8. Wildlife access critical to childrens health
9. In an enzyme critical for life, X-ray emission cracks mystery atom
10. Scripps research team achieves critical step to opening elusive class of compounds to drug discovery
11. NOAA designates critical habitat for black abalone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... 20, 2015 ... announced the addition of the  "5-year ... Recognition Market"  report to their offering.  ... service analyses trends in the iris ... commercial sectors, globally. Despite hardware pricing ...
(Date:5/18/2015)... Fingerprint Cards (FPC) has received an ... and FPC1035 from one if its module partners. Deliveries are ... 2015 and the sensors will be used by smartphone manufacturers ... 2015 hereby amount to 740 MSEK to date. In addition ... and a number of smaller orders not separately communicated amounting ...
(Date:5/11/2015)... N.Y. , May 11, 2015 Curemark ... announced the start of a new Phase III double ... of its novel formulation, CM-AT, on all children ages ... of its FDA Phase III double blinded clinical trial ... had low levels of the digestive enzyme chymotrypsin. This ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... Mayo Clinic-led researchers is first to devise a system ... killer that hunts down and destroys cancer cells -- ... an advanced electronic article of Nature Biotechnology. , The ... cells, and then redirected the virus to attack diseased, ...
... prenatal care, new research suggests that early infection may ... on the immune system. Researchers at the University of ... a one-time infection as newborns didn't learn as well ... after their immunity was challenged. The research is in ...
... that the antibiotic minocycline might help alleviate HIV's negative ... that can develop even though antiretroviral therapy controls the ... with simian immunodeficiency virus (SIV), a very close relative ... to brain cells, less brain inflammation, and less virus ...
Cached Biology News:Mayo Clinic Researchers Create 'Obedient Virus'; First Step To Use Measles Virus Against Cancer 2Rats infected as newborns grew up vulnerable to memory problems during an immune challenge 2Rats infected as newborns grew up vulnerable to memory problems during an immune challenge 3Antibiotic might fight HIV-induced neurological problems 2Antibiotic might fight HIV-induced neurological problems 3
(Date:6/1/2015)... , June 1, 2015  Fennec Pharmaceuticals, Inc. ... positive interim results from a poster presented today ... label randomised phase III trial of the efficacy ... patients receiving cisplatin (Cis) monotherapy for standard risk ... American Society of Clinical Oncology (ASCO) 2015 Annual ...
(Date:6/1/2015)... Minn. and SOUTH SAN FRANCISCO, ... Ventures, the venture arm of Baxter International Inc. (NYSE: ... Development, LLC ("VPD") today announced the formation of Vitesse ... initiated by Baxter Ventures to focus on the development ... immunology, hematology, and oncology. Following the spin-off of Baxter ...
(Date:6/1/2015)... June 1, 2015 Esperance Pharmaceuticals Inc. today ... lead candidate EP-100 in ovarian cancer patients resistant to ... seek and destroy cancer cells that overexpress luteinizing hormone-releasing ... over-expressed in a wide range of cancers. ... trial of EP-100 were presented at the 2015 ...
(Date:6/1/2015)... 29, 2015 Research and Markets ... of the "2015 Strategies in European ... their offering. This new 273-page ... diagnostic market, including emerging tests, technologies, instrumentation, ... of leading suppliers. Companies Mentioned: ...
Breaking Biology Technology:Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 2Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 3Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 4Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 2Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 3Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 4Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 5Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 2Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 3
... ... camera during an operation he performed for his Discovery Channel television special: Silent Stalker: ... ... Show used VizVOCUS,s popular "plug and play" medical camera during an ...
... England , May 25, 2010 Executives from Heptares,Therapeutics (Welwyn ... of the agreement under which O2h provides multi-FTE -synthetic,chemistry services to support ... , ... said, "We are happy to have signed,this new contract with O2h; they ...
... China , May 25 /PRNewswire-Asia-FirstCall/ -- Biostar,Pharmaceuticals, Inc. (Nasdaq: ... leading over-the-counter Hepatitis B medicine,Xin Aoxing Oleanolic Acid Capsule ("Xin Aoxing"), ... it has,commenced assembly of its production line for its proprietary Zushima ... ...
Cached Biology Technology:VizVOCUS's Digital Camera Used by Dr. Mehmet Oz on Discovery Channel Special 2Heptares Therapeutics Extends Multi-FTE Chemistry Collaboration With Oxygen Healthcare (O2h) 2Heptares Therapeutics Extends Multi-FTE Chemistry Collaboration With Oxygen Healthcare (O2h) 3Biostar Pharmaceuticals, Inc. Begins Assembly of New Production Line 2Biostar Pharmaceuticals, Inc. Begins Assembly of New Production Line 3Biostar Pharmaceuticals, Inc. Begins Assembly of New Production Line 4
RayBio Human Chemokine Antibody Array 1.1 (8) with Accessory, detects 38 chemokine factors (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
Vybrant® Multidrug Resistance Assay Kit...
... Platypus Contact Printing Kit contains choice ... with series of 100 / 200 micron ... or 200 um x 10 mm lines, ... 20, 40 or 60 nm and pitch ...
Request Info...
Biology Products: